Urinary Incontinence — CPB 0223 | AETNA Coverage Update

Aetna modified CPB 0223 for urinary incontinence, effective December 20, 2025. Here's what billing teams need to know about coverage criteria, excluded codes, and the action items that will protect your reimbursement.

Aetna, a CVS Health company, updated CPB 0223—its urinary incontinence coverage policy—on December 20, 2025. The policy governs a broad set of procedures including sacral nerve stimulation (CPT 64561, 64581), artificial urinary sphincter implantation (CPT 53445), peri-urethral bulking agent injections (CPT 51715), and urodynamic testing (CPT 51726–51729). Crucially, it also adds a growing list of not-covered codes—including newer neurostimulation Category III codes 0587T through 0590T and 0816T–0819T—that will trigger claim denial if billed for urinary incontinence indications.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Urinary Incontinence – CPB 0223
Policy Code	CPB 0223
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Urology, Urogynecology, Female Pelvic Medicine, Physical Therapy, General Surgery
Key Action	Audit charge capture for Category III neurostimulation codes (0587T–0590T, 0816T–0819T) and confirm all sacral nerve stimulator claims meet the three-part criteria before billing CPT 64561 or 64581

---

Aetna Urinary Incontinence Coverage Criteria and Medical Necessity Requirements 2025

The Aetna urinary incontinence coverage policy under CPB 0223 Aetna system covers a wide range of interventions—but every one of them carries specific medical necessity gates. There is no blanket coverage here. Miss a criterion, and you're looking at a denial.

Urodynamic Studies (CPT 51726, 51727, 51728, 51729, 51741)

Multi-channel urodynamic studies are medically necessary when two conditions are both present. First, the member must have symptoms and physical findings of urinary incontinence or voiding dysfunction—stress incontinence, overactive bladder, or lower urinary tract symptoms. Second, the provider must be considering invasive, potentially morbid, or irreversible treatment after conservative management has failed. Both boxes must be checked. Document both in the chart before billing CPT 51726 or any of its add-on codes.

Artificial Urinary Sphincter (CPT 53445, 53446, 53447, 53449, 53444)

Implantation of an artificial urinary sphincter is covered for intrinsic urethral sphincter deficiency (IUSD)—but only under four specific indications. Children with intractable UI refractory to behavioral or pharmacological therapy qualify, as long as they're unsuitable for other surgical corrections. Men who are six or more months post-prostatectomy with no improvement despite behavioral and pharmacological trials qualify. Members with epispadias-exstrophy after failed bladder neck reconstruction qualify. Women with intractable UI who have failed behavioral, pharmacological, and other surgical treatments qualify.

Outside those four groups, the AUS is considered experimental. If your patient doesn't fit one of these four buckets, prior authorization will not help you—the policy treats this as investigational.

Peri-Urethral Bulking Agents (CPT 51715, 11950, 11951, 11952, 11954)

Urinary incontinence billing for bulking agents requires that the member has intrinsic sphincter deficiency and has already failed conservative management—Kegel exercises, biofeedback, electrical stimulation, and/or pharmacotherapies. The FDA clearance of the agent matters here. Aetna names Bulkamid, Coaptite, Contigen, Durasphere, Macroplastique, and Uryx as covered examples. An off-label or non-FDA-cleared bulking agent won't pass medical necessity review.

There's a hard limit on reimbursement after three failed treatments. If the member's incontinence doesn't improve after three injections, Aetna won't cover additional bulking agent sessions. Track treatment count in your clinical documentation and flag these cases before billing a fourth session.

Sacral Nerve Stimulators (CPT 64561, 64581, 64590, 64595, 64585, 95970, 95971, 95972)

This is where the most claim denial risk sits. Aetna requires all three of the following for permanent implantation (Stage 2):

#	Covered Indication Copy
1	Urge UI or urge-frequency symptoms lasting at least six months that significantly limit daily activities
2	Failure of at least two anti-cholinergic drugs, or one anti-cholinergic plus mirabegron (beta-3 agonist), and failure of behavioral treatments including pelvic floor exercise, biofeedback, timed voids, and fluid management
3	Test stimulation (Stage 1, CPT 64561) showing at least 50% decrease in symptoms

Stage 1 test stimulation is separately covered for members who meet criteria one and two above. If you're billing Stage 2 without documented Stage 1 results showing ≥50% improvement, expect a denial. Make sure your trial period documentation is in the record before submitting the permanent implant claim.

---

Aetna Urinary Incontinence Exclusions and Non-Covered Indications

This section is where CPB 0223 gets expensive if your team isn't paying attention.

Category III Neurostimulation Codes — Not Covered

Aetna explicitly excludes the integrated single-device neurostimulation systems from coverage under this policy. That means CPT 0587T (percutaneous implantation), 0588T (revision or removal), 0589T (electronic analysis with simple programming), 0590T (electronic analysis with complex programming), 0816T and 0817T (open insertion variants), 0818T and 0819T (revision/removal variants), and 0988T (another open insertion variant) are all non-covered for bladder dysfunction indications under CPB 0223.

These codes represent newer device platforms. If your urology or urogynecology group has recently started using integrated neurostimulation systems and billing these Category III codes, check your Aetna claims immediately. Reimbursement under these codes is not supported by this policy.

Adjustable Balloon Continence Devices — Not Covered

CPT 53451, 53452, 53453, and 53454—the periurethral transperineal adjustable balloon continence device codes—are also non-covered under CPB 0223. This family of codes covers bilateral insertion, unilateral insertion, removal, and percutaneous adjustment. If you've been billing these for Aetna members, review outstanding claims.

Electrical Stimulation for Home Use — Not Covered

CPT 97014 (unattended electrical stimulation) and 97032 (manual electrical stimulation) are not covered for home use under this policy. The policy description includes that qualifier in the CPT descriptor itself—"not covered for home use." Supervised clinical electrical stimulation in a facility setting may be handled differently, but don't bill 97014 or 97032 for Aetna members receiving home-based incontinence treatment.

Other Non-Covered Treatments

PRP injections (CPT 0232T), acupuncture with electrical stimulation (CPT 97813, 97814), bariatric surgery codes (CPT 43644–43848 series), and hematopoietic progenitor cell transplantation (CPT 38241) are all listed as not covered for urinary incontinence indications. The bariatric codes appearing here likely reflect clinical context—obesity as a contributing factor to UI—but Aetna does not cover bariatric surgery under this policy.

---

Coverage Indications at a Glance

---

Aetna Urinary Incontinence Billing Guidelines and Action Items 2025

1. Audit Category III neurostimulation claims submitted on or after December 20, 2025.

Pull any Aetna claims with CPT codes 0587T, 0588T, 0589T, 0590T, 0816T, 0817T, 0818T, 0819T, or 0988T for urinary incontinence. These are not covered under CPB 0223. If you've submitted claims for these codes post-effective-date, initiate a refund review process with your compliance officer before Aetna triggers a recovery.

2. Verify sacral nerve stimulator claims include all three documented criteria.

Before billing CPT 64581 for permanent implantation, confirm the chart shows: six-plus months of urge UI with documented functional impact, failure of at least two anti-cholinergic agents or one anti-cholinergic plus mirabegron and failure of behavioral therapy, and Stage 1 test results with ≥50% symptom reduction. Missing any of these will get the claim denied. This is not a documentation technicality—it's a hard billing guidelines requirement.

3. Flag bulking agent cases at the third treatment.

When a member reaches three peri-urethral bulking agent sessions with CPT 51715 (or 11950–11954), document the outcome assessment at that visit. Aetna will not cover a fourth treatment if the first three haven't produced improvement. Proactively flag these cases in your scheduling or billing system before a fourth session is booked and billed.

4. Confirm FDA clearance for any bulking agent before billing.

Aetna's coverage policy specifically lists cleared agents. If your practice uses a newer or off-label bulking agent, verify it appears on the FDA-cleared list before submitting. A claim for an uncovered agent will deny on medical necessity grounds, and an appeal will be difficult to win without that FDA clearance documentation.

5. Remove CPT 97014 and 97032 from your Aetna charge capture for home-use incontinence treatment.

These electrical stimulation codes are excluded for home use under CPB 0223. If your charge capture or order sets include these codes in a home treatment context for Aetna members, correct that before you generate the next round of claims.

6. Talk to your compliance officer if you're seeing high volumes of the newly excluded Category III codes.

If integrated neurostimulation systems represent a significant portion of your Aetna urinary incontinence billing, the December 20, 2025 effective date creates real financial exposure. Get your compliance officer and billing consultant involved to assess the scope before you're managing a large-scale denial or recovery situation.

---

CPT, HCPCS, and ICD-10 Codes for Urinary Incontinence Under CPB 0223

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental CPT Codes

Other CPT Codes Related to CPB 0223

Code	Type	Description Copy
51992	CPT	Laparoscopy, surgical; sling operation for stress incontinence
57288	CPT	Sling operation for stress incontinence (e.g., fascia or synthetic)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full policy references 270 ICD-10-CM codes. Aetna's coverage policy for urinary incontinence spans a broad diagnosis range. Pull the complete list from the source policy at CPB 0223 on PayerPolicy to cross-reference your patient population.

---